Knapp F F, Goodman M M, Kirsch G, Reske S N, Kropp J, Biersack H J, Ambrose K R, Lambert C R, Goudonnet A
Nuclear Medicine Group, Health Sciences Research Division, Oak Ridge National Laboratory (ORNL), USA.
Ann Nucl Med. 1996 Feb;10(1):19-32. doi: 10.1007/BF03165050.
Introduction of geminal dimethyl-branching into the 3-position of 15-(p-iodophenyl) pentadecanoic acid (IPPA) significantly delays myocardial clearance in rats and dogs following intravenous administration. Several new analogues of DMIPP have been synthesized and evaluated in fasted rats. The effects of both the position of dimethyl-branching and the total chain-length of 3, 3-dimethyl analogues on heart uptake and clearance kinetics have been studied. In the first series of compounds, two methyl groups were introduced into the 3-, 4-, 6-, or 9- position. Tissue distribution studies of the 15-(p-[I-125] iodophenyl)-analogues demonstrated that the position of dimethyl-branching is an important factor affecting both myocardial specificity and retention. The [I-125] labeled 3,3- and 4,4-DMIPP analogues showed higher myocardial uptake and faster blood clearance than the 6,6- and 9,9-DMIPP analogues [heart, % dose/gm heart: blood), 30 min: 3,3-DMIPP = 5.06 (12:1); 4,4-DMIPP = 8.03 (16.7: 1); 6,6-DMIPP = 2.26 (3.1:1); 9,9-DMIPP = 3.06 (2.77)]. In the second series, the effects of total fatty acid chain length were evaluated with 3,3-dimethyl-substituted analogues with C11, C12, C13, C14, C15, and C19 chain lengths. The C14 and C15 chain length analogues showed the best properties [global heart: blood ratios): 30 min: C11, 0.70 (0.82); C12, 1.25 (0.68); C13, 0.47 (0.90); C14, 1.63 (3.54); C15, 5.06 (12); C19. 1.29 (0.82). These detailed studies have demonstrated that both total chain length and the position of geminal dimethyl-branching are important structural parameters which affect myocardial specificity and retention of omega-(p-iodophenyl)-substituted fatty acid analogues and that 3,3-DMIPP and 4,4-DMIPP are the best candidates with optimal properties for further study.
将偕二甲基支链引入15-(对碘苯基)十五烷酸(IPPA)的3位,在大鼠和犬静脉给药后可显著延缓心肌清除。已合成了几种DMIPP的新类似物并在禁食大鼠中进行了评估。研究了偕二甲基支链的位置和3,3-二甲基类似物的总链长对心脏摄取和清除动力学的影响。在第一系列化合物中,将两个甲基引入3、4、6或9位。15-(对-[I-125]碘苯基)类似物的组织分布研究表明,偕二甲基支链的位置是影响心肌特异性和滞留的重要因素。[I-125]标记的3,3-和4,4-DMIPP类似物比6,6-和9,9-DMIPP类似物表现出更高的心肌摄取和更快的血液清除率[心脏,%剂量/克心脏:血液),30分钟:3,3-DMIPP = 5.06(12:1);4,4-DMIPP = 8.03(16.7:1);6,6-DMIPP = 2.26(3.1:1);9,9-DMIPP = 3.06(2.77)]。在第二系列中,用具有C11、C12、C13、C14、C15和C19链长的3,3-二甲基取代类似物评估了总脂肪酸链长的影响。C14和C15链长的类似物表现出最佳性能[整体心脏:血液比率):30分钟:C11,0.70(0.82);C12,1.25(0.68);C13,0.47(0.90);C14,1.63(3.54);C15,5.06(12);C19,1.29(0.82)]。这些详细研究表明,总链长和偕二甲基支链的位置都是影响ω-(对碘苯基)取代脂肪酸类似物心肌特异性和滞留的重要结构参数,并且3,3-DMIPP和4,4-DMIPP是具有最佳性能的最佳候选物,可供进一步研究。